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Abstract: Background: The purpose was to assess tolerance to terbutaline after daily use of long-acting 2- agonist 
(LABA) and further to evaluate two designs of reversibility test widely used in research and clinic in order to demonstrate 
tolerance. 
Methods: Twenty-eight asthmatics were given daily LABA in 12 weeks and were randomized to challenge test and either 
conventional reversibility test with 2 puffs terbutaline or reversibility test with refracted doses (1 puff) every 5 min, total 4 
puffs. FEV1 was measured pre-challenge, post-challenge, during and after reversibility test. All subjects had 3 visits: 
baseline, after 4 weeks and after 12 weeks of LABA treatment. All subjects were non-smokers, aged 18–45 years and had 
a positive methacholine challenge. 
Results: The analyses showed a significant fall in reversibility after 4 and 12 weeks of LABA treatment (p=0.001) in the 
group with the conventional reversibility test. The group with reversibility test using refracted doses also showed a 
significant fall in reversibility after 4 weeks of LABA treatment (p=0.017) followed by a similar trend after 12 weeks 
(p=0.054), however, we experienced an interfering number of dropouts at the last visit. 
Conclusion: The bronchodilator response to terbutaline was significantly reduced in asthmatic subjects using daily LABA. 
The tolerance develops rapidly and is present after 4 weeks of treatment. Our study showed that both the conventional 
reversibility test and the reversibility test with refracted doses, combined with methacholine challenge is able to 
demonstrate tolerance to bronchodilator after daily use of LABA. 
Keywords: Tolerance, tachyphylaxis, -2-agonist, bronchodilator, asthma. 
INTRODUCTION 
 Long  acting  -2-agonists (LABA) are used in 
management of moderate to severe persistent asthma to gain 
asthma control. It is used as add-on therapy to inhaled 
corticosteroids (ICS) [1], either as a fixed combination (FC-
ICS/LABA) or in two devices, but LABA should never be 
used as a single drug due to the risk of serious adverse events 
in case of exacerbation [2]. Few studies, all with a low 
number of participants, have shown rapid and short lasting 
development of tolerance after regular use of LABA, few if 
any studies have shown long term development of tolerance, 
whereas other studies have shown significant disease control 
in those who had LABA added to their basic treatment with 
ICS [3-6]. 
  The purpose of the present study was to assess 
development of tolerance to terbutaline after short and long 
term regular use of salmeterol and to evaluate usefulness of 
two designs of reversibility tests in order to demonstrate this 
tolerance. Reduction in lung function was induced by a 
methacholine challenge test, followed by a conventional 
reversibility test with short acting -2-agonist (SABA) 
inhaling 1 mg terbutaline and measurement of FEV1 before 
and 15 minutes after inhalation of terbutaline [7]. The   
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conventional reversibility test is the most frequently used 
reversibility test in clinical work. Lastly, another designed 
reversibility test with SABA given in refracted doses 
followed by consecutive measurements of FEV1 5 minutes 
after each dose of SABA, giving a total response time of 20 
minutes [8]. Because, the reversibility test with refracted 
doses is used in research studies we wanted to assess this 
design as well. 
MATERIAL AND METHODS 
  Volunteers who responded to an advertisement in a local 
newspaper were invited to a screening session with 
assessments of fractional exhaled NO (FeNO), spirometry, 
methacholine challenge test, and measurement of 
height/weight and skin prick test. Inclusion criteria were: 1) 
diagnosis of asthma based on a clinical history and 
symptoms; 2) age between 18 to 45 years; 3) a positive 
methacholine challenge test with PD20 < 7.8 micromol. 
Exclusion criteria were: 1) other medical co-morbidities; 2) 
respiratory tract infections within 14 days before enrollment; 
3) use of oral corticosteroids within the last 3 months and 
current smoking or history of smoking (more than 10 
packyears). 
  Conventional reversibility test was performed with two 
puffs Terbutaline (total 1 mg as dry powder) immediately 
after the methacholine challenge with measurement of FEV1 
after 15 minutes [7]. Reversibility test with refracted doses 
was performed with one puff Terbutaline (0.5 mg as dry 
powder) immediately after the methacholine challenge and Daily Use of LABA Causes Tolerance  The Open Respiratory Medicine Journal, 2010, Volume 4    49 
one puff after 5, 10 and 15 minutes with measurement of 
FEV1 at 5, 10, 15 and 20 minutes after the challenge [6, 8]. 
  The present survey was performed as a follow-up study 
with three visits at week 0 (visit 0), 4 (visit 1) and 12 (visit 
2). All visits included interview, measurement of FeNO, 
lung function, methacholine challenge test, reversibility test 
and at visit 0 validated questionnaires (ACQ and 
MiniAQLQ) [9]. Subjects received 50 micrograms 
salmeterol twice daily. All subjects were instructed to start 
treatment at visit 0 (week 0) and not to take medicine 12 
hours before visit 1 (week 4) and visit 2 (week 12). The 
study medication was salmeterol/fluticasone proprionate 
50+250 microgram/dose (Advair Diskus
®). 
ANALYSIS 
  The main outcome was reversibility after methacholine 
challenge, expressed as the raise in FEV1 after 15 min at the 
conventional reversibility test and after 20 min at the 
reversibility test with refracted doses. Mean and standard 
deviations were calculated for the normally distributed data. 
Paired data were analyzed by paired T-tests. Values of 
p<0.05 were considered statistical significant and power was 
set to 80%. Sample size calculations were based on previous 
studies by using methacholine [6]. The Ethical Committee of 
Copenhagen, Denmark approved the study, no. H-C-2007-
0132 and written informed consent was obtained from all 
participants before the first clinical examination. 
RESULTS 
  After the screening session twenty-eight of 54 subjects 
were enrolled and randomized: 14 to conventional 
reversibility test and 14 to reversibility test with refracted 
doses. Seven dropouts were recorded during the study, 3 at 
four weeks, and 4 at 12 weeks. 
  Of 28 subjects randomized to the study, 13 subjects were 
men with 6 and 7 in each group. We found no baseline 
differences in mean (SD) between participants in the 
conventional and refracted group in age (32 (8) vs 30 (10) 
years respectively), FEV1 (3.50 L (0.97) vs 3.22 L (0.63) 
respectively), and FEV1/FVC (75% (8) vs 79% (10) 
respectively). None of the subjects in the group with 
conventional reversibility test used daily ICS, while 7 
subjects in the group with reversibility test with refracted 
doses used daily ICS. At baseline ACQ median was 1.88 and 
miniAQLQ median 5.48 in conventional reversibility test 
group and ACQ median was 1.72 and miniAQLQ 5.69 in the 
group with reversibility test with refracted doses. 
  FeNO was 41.5 ppb (visit 0), 19.1 ppb (visit 1), and 21.7 
ppb (visit 2) in conventional reversibility test group. In the 
group with reversibility test with refracted doses FeNO was 
32.1 (visit 0), 21.2 (visit 1), and 21.3 (visit 2). 
  There was no significant clinical or statistical difference 
in pre-challenge mean (SD) FEV1 (L) between the visits 
within the groups: 3.50 (0.97), 3.67 (1.05), 3.78 (0.93) 
respectively in conventional reversibility test vs 3.22 (0.63), 
3.16 (0.38), 3.19 (0.28) respectively in the reversibility test 
with refracted doses. 
  At the three visits the mean (SD) FEV1 (L) after 
bronchial challenge was 2.63 (0.72), 2.83 (0.80), 2.93 (0.76) 
respectively in the conventional reversibility test and 2.54 
(0.48), 2.49 (0.42), 2.50 (0.36) respectively in reversibility 
test with refracted doses. This corresponds to a mean 
reduction in FEV1 during provocation of 0.87 L, 0.84 L, 0.85 
L respectively in conventional reversibility test and 0.68 L, 
0.67 L, 0.69 L respectively in reversibility with refracted 
doses, although receiving ICS treatment during a 12 weeks 
period. 
  In the group with conventional reversibility test there was 
a significant reduction in reversibility after methacholine 
challenge at visit 1 compared to visit 0, i.e. after regular 
treatment with LABA with the mean difference in FEV1 after 
reversibility 0.56 L with CI (0.26 – 0.85) (p = 0.001). The 
mean difference in FEV1 after reversibility at visit 2 
compared to visit 0 was 0.61 L with CI (0.37 – 0.84) 
(p=0.001). If expressed as percentage of reduction in FEV1 
after reversibility the mean difference between visit 1 and 0 
was 21% with CI (10 – 32) (p=0.001) and between visit 2 
and 0 was 24% with CI (12 – 36) (p=0.001). 
  We observed a significant reduction in reversibility with 
refracted doses after methacholine challenge at visit 1 
compared to visit 0. Mean difference in FEV1 after 
reversibility was 0.26 L with CI (0.06 – 0.47) (p=0.017). 
There was no significant difference in reversibility at visit 2 
compared to visit 0, however, we experienced an interfering 
numbers of dropouts at the last visit. Mean difference was 
0.28 L with CI (-0.007 – 0.56) (p=0.054). During the study 
the two groups received identical medication. There is no 
explanation for the dropouts at the last visit in one group. 
DISCUSSION 
  Our study has shown that regular use of salmeterol 
results in decreased response to terbutaline after 
methacholine challenge, i.e. tolerance to bronchodilator. This 
confirms previous findings by Hancox et al. [8-10], whom 
found that eight asthmatics showed development of tolerance 
after one week of LABA treatment. The present findings 
show, that giving a combination of ICS and LABA does not 
protect towards development of decrease in lung function 
during provocation, and furthermore no protection of FC-
ICS/LABA was found towards development of tolerance 
during a sufficient period of treatment of 4 and 12 weeks, 
which confirms previous findings [10]. 
  The new perspective in evaluation of two types of 
reversibility test shows that the conventional reversibility 
test is a valid method to detect tolerance to LABA. The 
conventional reversibility test is widely used in the clinical 
work, whereas the method mostly used in research is 
reversibility test with refracted doses of SABA. 
  In conclusion, we found that asthmatic subjects on fixed 
combination of ICS and LABA are in risk of developing 
treatment resistant decrease in lung function. 
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